Date: 2011-07-26
Type of information: Capital increase
Company: BioAlliance Pharma (France)
Investors:
Amount: €16.64 million
Funding type: capital increase
Planned used: The raised funds will enable:
Others: BioAlliance Pharma has announced its successful capital increase, with maintenance of preferential subscription rights launched on July 1st, 2011, for a total of €16,64 million raised. As the transaction was oversubscribed, all shares from the offer (3,395,943 new ordinary shares) will therefore be issued for a gross total amount of 16,640,120 Euros. The share capital will thus be increased from €3,395,943 to €4,244,928.75 divided into 16,979,715 shares of €0.25 nominal value per share. The settlement and delivery of the new shares will occur on August 1, 2011 and 3,395,943 new shares will be listed on NYSE Euronext Paris on August 2, 2011 on the same listing line as the existing shares of the company.
Therapeutic area: Cancer - Oncology - Rare diseases
